SG11201609615UA - Nampt inhibitors and methods - Google Patents
Nampt inhibitors and methodsInfo
- Publication number
- SG11201609615UA SG11201609615UA SG11201609615UA SG11201609615UA SG11201609615UA SG 11201609615U A SG11201609615U A SG 11201609615UA SG 11201609615U A SG11201609615U A SG 11201609615UA SG 11201609615U A SG11201609615U A SG 11201609615UA SG 11201609615U A SG11201609615U A SG 11201609615UA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- nampt inhibitors
- nampt
- inhibitors
- Prior art date
Links
- 102100033223 Nicotinamide phosphoribosyltransferase Human genes 0.000 title 1
- 108010064862 Nicotinamide phosphoribosyltransferase Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0635—B lymphocytes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462001905P | 2014-05-22 | 2014-05-22 | |
PCT/US2015/032170 WO2015179759A1 (en) | 2014-05-22 | 2015-05-22 | Nampt inhibitors and methods |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201609615UA true SG11201609615UA (en) | 2016-12-29 |
Family
ID=53366297
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201609615UA SG11201609615UA (en) | 2014-05-22 | 2015-05-22 | Nampt inhibitors and methods |
SG10201810263QA SG10201810263QA (en) | 2014-05-22 | 2015-05-22 | Nampt inhibitors and methods |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201810263QA SG10201810263QA (en) | 2014-05-22 | 2015-05-22 | Nampt inhibitors and methods |
Country Status (15)
Country | Link |
---|---|
US (2) | US10017523B2 (ko) |
EP (1) | EP3145933B1 (ko) |
JP (1) | JP6580597B2 (ko) |
KR (1) | KR20170005865A (ko) |
CN (1) | CN106661044B (ko) |
AR (1) | AR100588A1 (ko) |
AU (1) | AU2015263980A1 (ko) |
BR (1) | BR112016026905A8 (ko) |
CA (1) | CA2948878A1 (ko) |
IL (1) | IL249086A0 (ko) |
MX (1) | MX2016015298A (ko) |
RU (1) | RU2016150395A (ko) |
SG (2) | SG11201609615UA (ko) |
TW (1) | TW201625641A (ko) |
WO (1) | WO2015179759A1 (ko) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MA46660A (fr) | 2016-10-18 | 2019-08-28 | Seattle Genetics Inc | Administration ciblée d'inhibiteurs de la voie de récupération de nicotinamide adénine dinucléotide |
CN110799217A (zh) | 2017-04-27 | 2020-02-14 | 西雅图基因公司 | 季铵化烟酰胺腺嘌呤二核苷酸补救途径抑制剂缀合物 |
US20230321086A1 (en) * | 2020-11-20 | 2023-10-12 | Universiy of Pittsburgh - of the Commonwealth System of Higher Education | Methods and materials for inhibiting nicotinamide phosphoribosyltransferase activity |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CZ303572B6 (cs) | 2000-06-28 | 2012-12-12 | Smithkline Beecham P. L. C. | Jemne rozmelnený prostredek a zpusob jeho prípravy |
TW200804393A (en) * | 2005-11-14 | 2008-01-16 | Solvay Pharm Gmbh | Novel N-sulfamoyl-N'-benzopyranpiperidines for medical use |
WO2007088462A1 (en) * | 2006-02-01 | 2007-08-09 | Pfizer Products Inc. | Spirochromane antagonists of the h-3 receptor |
WO2012077655A1 (ja) * | 2010-12-07 | 2012-06-14 | 塩野義製薬株式会社 | Gpr119アゴニスト活性を有するスピロ誘導体 |
EP2766352B1 (en) * | 2011-10-12 | 2018-06-06 | University Health Network (UHN) | Indazole compounds as kinase inhibitors and method of treating cancer with same |
CA2855510A1 (en) * | 2011-11-11 | 2013-05-16 | Abbvie Inc. | Nampt inhibitors |
US9193723B2 (en) * | 2012-05-11 | 2015-11-24 | Abbvie Inc. | NAMPT inhibitors |
-
2015
- 2015-05-21 TW TW104116291A patent/TW201625641A/zh unknown
- 2015-05-22 US US15/312,482 patent/US10017523B2/en active Active
- 2015-05-22 AR ARP150101612A patent/AR100588A1/es unknown
- 2015-05-22 RU RU2016150395A patent/RU2016150395A/ru not_active Application Discontinuation
- 2015-05-22 CA CA2948878A patent/CA2948878A1/en not_active Abandoned
- 2015-05-22 MX MX2016015298A patent/MX2016015298A/es unknown
- 2015-05-22 WO PCT/US2015/032170 patent/WO2015179759A1/en active Application Filing
- 2015-05-22 SG SG11201609615UA patent/SG11201609615UA/en unknown
- 2015-05-22 SG SG10201810263QA patent/SG10201810263QA/en unknown
- 2015-05-22 EP EP15727798.9A patent/EP3145933B1/en active Active
- 2015-05-22 AU AU2015263980A patent/AU2015263980A1/en not_active Abandoned
- 2015-05-22 CN CN201580039570.4A patent/CN106661044B/zh active Active
- 2015-05-22 BR BR112016026905A patent/BR112016026905A8/pt not_active IP Right Cessation
- 2015-05-22 KR KR1020167035746A patent/KR20170005865A/ko unknown
- 2015-05-22 JP JP2016568840A patent/JP6580597B2/ja active Active
-
2016
- 2016-11-21 IL IL249086A patent/IL249086A0/en unknown
-
2018
- 2018-07-03 US US16/026,901 patent/US20180312525A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20170107231A1 (en) | 2017-04-20 |
AR100588A1 (es) | 2016-10-19 |
WO2015179759A1 (en) | 2015-11-26 |
SG10201810263QA (en) | 2018-12-28 |
CN106661044B (zh) | 2019-03-22 |
BR112016026905A8 (pt) | 2021-07-20 |
US20180312525A1 (en) | 2018-11-01 |
EP3145933A1 (en) | 2017-03-29 |
AU2015263980A1 (en) | 2018-08-16 |
EP3145933B1 (en) | 2021-03-17 |
IL249086A0 (en) | 2017-01-31 |
BR112016026905A2 (pt) | 2017-08-15 |
TW201625641A (zh) | 2016-07-16 |
RU2016150395A (ru) | 2018-06-25 |
US10017523B2 (en) | 2018-07-10 |
JP6580597B2 (ja) | 2019-09-25 |
JP2017516774A (ja) | 2017-06-22 |
KR20170005865A (ko) | 2017-01-16 |
CN106661044A (zh) | 2017-05-10 |
CA2948878A1 (en) | 2015-11-26 |
RU2016150395A3 (ko) | 2019-01-16 |
MX2016015298A (es) | 2017-03-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL287113A (en) | smyd inhibitors | |
ZA201700241B (en) | Mnk inhibitors and methods related thereto | |
IL251584A0 (en) | Dihydropyrrolopyridines ror-gamma inhibitors | |
IL246902B (en) | Dihydropyrrolopyridine ror–gamma inhibitors | |
HK1243072A1 (zh) | 布羅莫結構域抑制劑及其用途 | |
HK1243415A1 (zh) | 溴結構域抑制劑 | |
FI3215147T3 (fi) | Hermostoa salpaavia norketamiiniyhdisteitä ja -menetelmiä | |
IL248895A0 (en) | Phosphatidylinositol 3-kinase inhibitors | |
GB201617085D0 (en) | Compare and delay instructions | |
GB201521059D0 (en) | Inhibitors of metallo-beta-lactamases | |
HK1243342A1 (zh) | 化合物和方法 | |
GB201501004D0 (en) | Inhibitors | |
HK1250926A1 (zh) | 抑制劑及其應用 | |
IL249086A0 (en) | nampt inhibitors and methods | |
GB201520949D0 (en) | Inhibitors | |
GB201507707D0 (en) | Components and methods for formation of components | |
GB201505975D0 (en) | Inhibitors and their uses | |
GB201505971D0 (en) | Inhibitors and their uses | |
GB201418154D0 (en) | Inhibitors | |
GB201421109D0 (en) | Insert and method |